Log in to search using one of your social media accounts:

 

Surge in gun sales after Sandy Hook shooting led to spike in accidental gun deaths, study says

In the days after the horrific shooting at Sandy Hook Elementary School, gun enthusiasts rushed to buy millions of firearms, driven by fears that the massacre would spark new gun legislation. Those restrictions never became a reality, but a new study concludes that all the additional guns caused a significant jump in accidental firearm deaths. […]Related:A mother got the flu from her children — and was dead two days laterGene therapy makes a big advance treating hemophilia B blood disorderAn Illinois doctor traded drugs for sex and cash. He just pleaded guilty.
Source: Washington Post: To Your Health - Category: Consumer Health News Source Type: news

Related Links:

Authors: Ragni MV Abstract Inhibitor formation is among the most severe complications of hemophilia treatment. With a cumulative incidence of ∼30% in those with severe hemophilia A and ∼3% in those with severe hemophilia B, inhibitors are caused by a T-cell response directed against infused coagulation factor; these inhibitors neutralize factor VIII or IX activity and disrupt normal hemostasis. Inhibitor patients become unresponsive to standard factor treatment and, as an alternative, use bypass treatment (eg, recombinant factor VIIa or factor VIII inhibitor bypass activity). However, response to bypass age...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Authors: Iorio A Abstract Prevention and treatment of bleeding in hemophilia requires that plasma clotting factor activity of the replaced factor exceeds a defined target level. Most clinical decisions in hemophilia are based on implicit or explicit application of pharmacokinetic measures. The large interindividual variability in pharmacokinetics of factor concentrates suggests that relying on the average pharmacokinetic characteristics of factor concentrates would not allow optimizing the treatment of individual patients; for example, adjusting the frequency of infusions and targeting a specific clotting factor ac...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Authors: George LA Abstract Concurrent with the development of recombinant factor replacement products, the characterization of the F9 and F8 genes over 3 decades ago allowed for the development of recombinant factor products and made the hemophilias a target disease for gene transfer. The progress of hemophilia gene therapy has been announced in 3 American Society of Hematology scientific plenary sessions, including the first "cure" in a large animal model of hemophilia B in 1998, first in human sustained vector-derived factor IX activity in 2011, and our clinical trial results reporting sustained vector...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Emicizumab prophylaxis, recently approved for adult and pediatric patients with hemophilia A with inhibitors to factor VIII, has additional support from the HAVEN 2 study in pediatric patients.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
A gene-therapy-based approach reports that an adenovirus-based cassette was able to carry and deliver the culprit missing gene for hemophilia A: factor VIII.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New therapies are creating excitement for the treatment of a terrible disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:BMRN NASDAQ:ONCE NASDAQ:SHPG NYSE:NVO NYSE:PFE Source Type: news
Roche announced today that new data from the ongoing Hemlibra ® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Coming just days after reports of a gene therapy that pushed the bleeding disorder hemophilia B into remission, new research suggests the same could be true for adults with the "A" form of the disease.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Coming just days after reports of a gene therapy that pushed the bleeding disorder hemophilia B into remission, new research suggests the same could be true for adults with the "A" form of the disease.
Source: WebMD Health - Category: Consumer Health News Source Type: news
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
More News: Children | Haemophilia | Health | Hemophilia | Study